Table 3.
Multivariate Cox proportional hazards regression analysis of MACEs
| Model | PCSK9 1-SD increase | PCSK9 T1 | PCSK9 T2 | PCSK9 T3 |
|---|---|---|---|---|
| Crude | 1.92 (1.43–2.57)† | 1.00 (Reference) | 2.57 (0.90–7.33) | 4.44 (1.62–12.18)† |
| Model 1 | 1.99 (1.46–2.68)† | 1.00 (Reference) | 2.76 (0.96–7.95) | 4.85 (1.74–13.54)† |
| Model 2 | 1.95 (1.41–2.70)† | 1.00 (Reference) | 2.94 (1.00–8.63) | 3.93 (1.35–11.42)* |
| Model 3 | 1.86 (1.29–2.69)* | 1.00 (Reference) | 3.36 (1.11–10.22)* | 3.76 (1.16–12.27)* |
| Model 4 | 1.86 (1.31–2.65)* | 1.00 (Reference) | 3.30 (1.09–10.01)* | 3.70 (1.16–11.82)* |
*p < 0.05; †p < 0.01
Model 1 adjusted for age and sex; Model 2 adjusted for Model 1 plus body mass index, baseline statin use, prior coronary artery disease, hypertension, diabetes and current smoking; Model 3 adjusted for Model 2 plus low- and high-density lipoprotein cholesterol, total cholesterol, apolipoprotein B, lipoprotein (a) and high sensitivity C-reactive protein; Model 4 adjusted for Model 3 plus genetic mutations. PCSK9, proprotein convertase subtilisin-kexin type 9; MACE: major adverse cardiovascular events